HEPAHepion Pharmaceuticals, Inc.同业对比
Hepion Pharmaceuticals, Inc. 与Pharmaceutical Preparations的逐项对比:市值、估值、增长、盈利能力、质量与总回报,以及在同业组内的排名。所有数值均由引擎从 SEC 申报与延迟行情计算,排名仅为组内排序位置 —— 描述性数据,非投资建议。
完整同业对比
同业组:同 SIC 行业分类 (Pharmaceutical Preparations)| 公司 | 市值 | 市盈率(TTM) | 市净率 | 市销率 | 营收同比增长 | 净利同比增长 | 息税前利润率 | 净资产收益率 | 投入资本回报率 | 皮氏 F 值 | 一年总回报 | 股息率 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HEPA本股 | $29M#8 | — | 22.4x#12 | — | — | 37.3%#6 | — | -647.5%#11 | — | — | -17.6%#5 | — |
| ABVC | $31M#3 | — | 3.0x#8 | 105.4x#7 | 0.0%#3 | -61.3%#13 | -2416.0%#7 | -76.9%#5 | -68.5%#5 | — | -57.1%#10 | — |
| BRNS | $31M#4 | — | 0.5x#2 | — | -100.0%#9 | -8.8%#10 | — | -116.4%#8 | — | — | -37.0%#8 | — |
| CPHI | $31M#5 | — | 0.9x#4 | 7.5x#3 | -8.5%#5 | 32.7%#7 | -78.2%#1 | -8.8%#3 | -7.7%#2 | 5#1 | -63.5%#11 | — |
| KYNB | $31M#6 | 0.2x#1 | — | 4.8x#2 | -78.3%#7 | 485.6%#1 | -712.7%#6 | — | — | — | -33.8%#6 | — |
| RNAZ | $31M#7 | — | — | — | — | -106.9%#14 | — | — | — | — | -83.9%#13 | — |
| NNVC | $31M#2 | — | 3.4x#9 | — | — | -14.1%#11 | — | -103.4%#6 | -89.9%#6 | — | 1.8%#2 | — |
| APUS | $3M#16 | — | 0.0x#1 | — | — | -331.7%#15 | — | -5.6%#2 | -11.2%#3 | — | -89.4%#15 | — |
| IGC | $28M#9 | — | 4.6x#10 | 22.2x#6 | -5.5%#4 | 45.2%#5 | -585.8%#5 | -116.1%#7 | -125.5%#7 | 3#3 | -34.2%#7 | — |
| NXTC | $26M#10 | — | 2.2x#7 | 1.2x#1 | 252.6%#1 | -0.3%#9 | -257.5%#3 | -459.7%#10 | — | — | 0.5%#3 | — |
| TXMD | $25M#11 | — | 0.9x#6 | 8.4x#4 | 71.6%#2 | 73.9%#2 | -145.3%#2 | -2.1%#1 | -3.8%#1 | 5#1 | 93.8%#1 | — |
| ACTU | $24M#12 | — | 24.3x#13 | — | — | 18.5%#8 | — | -2247.2%#13 | — | — | -85.6%#14 | — |
| ATOS | $24M#13 | — | 0.9x#5 | 13623.6x#8 | -95.6%#8 | -36.3%#12 | -2112684.9%#8 | -129.6%#9 | — | — | -80.7%#12 | — |
| LTGO | $1.6B#1 | — | — | — | — | — | — | — | — | — | — | — |
| CLRB | $23M#14 | — | 0.8x#3 | — | — | 51.1%#3 | — | -72.9%#4 | — | — | -54.7%#9 | — |
| COCP | $22M#15 | — | 21.1x#11 | 11.0x#5 | -69.3%#6 | 49.5%#4 | -447.8%#4 | -845.9%#12 | -20.4%#4 | 3#3 | -5.4%#4 | — |
数值来自 SEC 申报与延迟行情;排名仅为该组内的排序位置 —— 描述性数据,不构成评级或建议。 数据构建于 2026-09-18。
数据来自 SEC XBRL 申报与延迟行情 · 排名为组内排序 · 仅供参考 · 非投资建议